|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0027651,
umls-concept:C0178638,
umls-concept:C0520484,
umls-concept:C1384573,
umls-concept:C1414662,
umls-concept:C1522485,
umls-concept:C1527144,
umls-concept:C1704867,
umls-concept:C1707455,
umls-concept:C1708632,
umls-concept:C2003941
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2009-9-1
|
|
pubmed:abstractText |
The mouse monoclonal antibody MOv18, directed against the alpha-isoform of folate receptor (FR), was investigated to identify the optimal radioconjugate for radioimmunotherapy of minimal residual disease in ovarian cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Carrier Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Folate Receptors, GPI-Anchored,
http://linkedlifedata.com/resource/pubmed/chemical/Iodine Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Lutetium,
http://linkedlifedata.com/resource/pubmed/chemical/MOv18 monoclonal antibody,
http://linkedlifedata.com/resource/pubmed/chemical/Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cell Surface,
http://linkedlifedata.com/resource/pubmed/chemical/Yttrium Radioisotopes
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1872-9614
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
36
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
759-70
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19720288-Animals,
pubmed-meshheading:19720288-Antibodies, Monoclonal,
pubmed-meshheading:19720288-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:19720288-Carrier Proteins,
pubmed-meshheading:19720288-Cell Line, Tumor,
pubmed-meshheading:19720288-Female,
pubmed-meshheading:19720288-Folate Receptors, GPI-Anchored,
pubmed-meshheading:19720288-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19720288-Humans,
pubmed-meshheading:19720288-Iodine Radioisotopes,
pubmed-meshheading:19720288-Isotope Labeling,
pubmed-meshheading:19720288-Lutetium,
pubmed-meshheading:19720288-Maximum Tolerated Dose,
pubmed-meshheading:19720288-Mice,
pubmed-meshheading:19720288-Neoplasms,
pubmed-meshheading:19720288-Radioimmunotherapy,
pubmed-meshheading:19720288-Radioisotopes,
pubmed-meshheading:19720288-Receptors, Cell Surface,
pubmed-meshheading:19720288-Time Factors,
pubmed-meshheading:19720288-Tissue Distribution,
pubmed-meshheading:19720288-Transplantation, Heterologous,
pubmed-meshheading:19720288-Tumor Burden,
pubmed-meshheading:19720288-Yttrium Radioisotopes
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
(177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts.
|
|
pubmed:affiliation |
Unit of Molecular Therapies, Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
